Completed
Pilot Study of Denileukin Diftitox Plus High-Dose IL-2 for Patients With Metastatic Renal Cancer
NCT00278369
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
- Locations
-
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University Chicago, Illinois, United States